Logo image of LPCN

LIPOCINE INC (LPCN) Stock Fundamental Analysis

USA - NASDAQ:LPCN - US53630X2036 - Common Stock

2.87 USD
+0.05 (+1.77%)
Last: 11/14/2025, 8:00:00 PM
2.961 USD
+0.09 (+3.17%)
After Hours: 11/14/2025, 8:00:00 PM
Fundamental Rating

4

Overall LPCN gets a fundamental rating of 4 out of 10. We evaluated LPCN against 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for LPCN as it has an excellent financial health rating, but there are worries on the profitability. LPCN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LPCN was profitable.
LPCN had a negative operating cash flow in the past year.
LPCN had negative earnings in 4 of the past 5 years.
In the past 5 years LPCN always reported negative operating cash flow.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.27%, LPCN is in line with its industry, outperforming 56.25% of the companies in the same industry.
Looking at the Return On Equity, with a value of -26.32%, LPCN is in the better half of the industry, outperforming 61.98% of the companies in the same industry.
Industry RankSector Rank
ROA -24.27%
ROE -26.32%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LPCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LPCN has been increased compared to 1 year ago.
Compared to 5 years ago, LPCN has more shares outstanding
LPCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -8.59, we must say that LPCN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.59, LPCN is doing worse than 65.63% of the companies in the same industry.
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.59
ROIC/WACCN/A
WACC8.88%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 12.71 indicates that LPCN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.71, LPCN belongs to the best of the industry, outperforming 83.85% of the companies in the same industry.
LPCN has a Quick Ratio of 12.71. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.71, LPCN belongs to the best of the industry, outperforming 83.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.71
Quick Ratio 12.71
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

8

3. Growth

3.1 Past

LPCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 168.92%, which is quite impressive.
Measured over the past years, LPCN shows a very strong growth in Earnings Per Share. The EPS has been growing by 213.46% on average per year.
Looking at the last year, LPCN shows a very strong growth in Revenue. The Revenue has grown by 492.81%.
LPCN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 133.89% yearly.
EPS 1Y (TTM)168.92%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%-43.9%
Revenue 1Y (TTM)492.81%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LPCN will show a very negative growth in Earnings Per Share. The EPS will decrease by -39.74% on average per year.
LPCN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.92% yearly.
EPS Next Y-222.86%
EPS Next 2Y-77.83%
EPS Next 3Y-39.74%
EPS Next 5YN/A
Revenue Next Year-88.42%
Revenue Next 2Y-76.71%
Revenue Next 3Y-13.85%
Revenue Next 5Y37.92%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 5.63 indicates a rather cheap valuation of LPCN.
95.83% of the companies in the same industry are more expensive than LPCN, based on the Price/Earnings ratio.
LPCN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.89.
LPCN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 5.63
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as LPCN's earnings are expected to decrease with -39.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-77.83%
EPS Next 3Y-39.74%

More info and screens

0

5. Dividend

5.1 Amount

LPCN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPOCINE INC

NASDAQ:LPCN (11/14/2025, 8:00:00 PM)

After market: 2.961 +0.09 (+3.17%)

2.87

+0.05 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners9.81%
Inst Owner Change0.18%
Ins Owners2.91%
Ins Owner Change0%
Market Cap15.56M
Revenue(TTM)11.20M
Net Income(TTM)-4.51M
Analysts82.5
Price Target7.52 (162.02%)
Short Float %2.07%
Short Ratio3.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.74%
Min EPS beat(2)-0.49%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)143.62%
Min EPS beat(4)-0.49%
Max EPS beat(4)555.88%
EPS beat(8)6
Avg EPS beat(8)87.86%
EPS beat(12)8
Avg EPS beat(12)54.61%
EPS beat(16)11
Avg EPS beat(16)136.69%
Revenue beat(2)1
Avg Revenue beat(2)46.31%
Min Revenue beat(2)-74.1%
Max Revenue beat(2)166.72%
Revenue beat(4)2
Avg Revenue beat(4)5.89%
Min Revenue beat(4)-100%
Max Revenue beat(4)166.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)49.67%
Valuation
Industry RankSector Rank
PE 5.63
Fwd PE N/A
P/S 3.7
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)0.51
EY17.77%
EPS(NY)-1.79
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.78
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.02
Profitability
Industry RankSector Rank
ROA -24.27%
ROE -26.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.71
Quick Ratio 12.71
Altman-Z -8.59
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)521.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.92%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%-43.9%
EPS Next Y-222.86%
EPS Next 2Y-77.83%
EPS Next 3Y-39.74%
EPS Next 5YN/A
Revenue 1Y (TTM)492.81%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A
Revenue Next Year-88.42%
Revenue Next 2Y-76.71%
Revenue Next 3Y-13.85%
Revenue Next 5Y37.92%
EBIT growth 1Y42.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.39%
OCF growth 3YN/A
OCF growth 5YN/A

LIPOCINE INC / LPCN FAQ

What is the ChartMill fundamental rating of LIPOCINE INC (LPCN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LPCN.


Can you provide the valuation status for LIPOCINE INC?

ChartMill assigns a valuation rating of 2 / 10 to LIPOCINE INC (LPCN). This can be considered as Overvalued.


What is the profitability of LPCN stock?

LIPOCINE INC (LPCN) has a profitability rating of 1 / 10.


Can you provide the financial health for LPCN stock?

The financial health rating of LIPOCINE INC (LPCN) is 7 / 10.


What is the expected EPS growth for LIPOCINE INC (LPCN) stock?

The Earnings per Share (EPS) of LIPOCINE INC (LPCN) is expected to decline by -222.86% in the next year.